ABOUT DATACUBED HEALTH

Datacubed Health is a pioneering patient engagement and eCOA company making better science and healthier communities a reality. Datacubed applies individualized solutions for the capture of active and passive data for engagement with patients in in-person, hybrid or fully virtual clinical studies. Focusing on healthcare and life sciences, Datacubed offers software and services driven by behavioral science to improve patient retention and compliance, resulting in better data and positive health outcomes. For more information, please visit datacubed.com

VIDEOS & WEBINARS

  • Watch the below video of an ePRO and eDiary solution that leverages behavioral science to increase compliance and retention rates.

  • While COVID-19 has ushered in some much-needed innovations in terms of technology solutions to power decentralized, not all solutions are created equal. When evaluating mHealth technology, for example, the integrity of data collection and data privacy are paramount. In this webinar we discuss the key considerations when making an investment in an mHealth platform.

  • See how Datacubed Health geofencing makes clinical event data capture easy and convenient for participants.

CONTACT INFORMATION

Datacubed Health

384 Bridge Street 4th Floor

Brooklyn, NY 11201

UNITED STATES

Contact: Dana Connor

FEATURED ARTICLES

  • Over the past year and a half, the decentralized trial (DCT) model has helped many studies stay on track amid the disruption of the COVID-19 pandemic.  And yet, the pandemic was not the genesis of decentralized trials.

  • Patient recruitment and retention drives the high cost of clinical trials. As a result, patient resources can be leveraged throughout all phases of a study to reduce trial costs, shorten timelines, and improve the overall patient experience.

  • Social media companies make big investments to increase people’s engagement with their platforms. In the available blog post, read how in the clinical trial space, enhancing engagement of patients is an increasingly hot topic.

  • In this blog, the must haves for decentralized trials is discussed through the lens of a breast cancer survivor.

  • The National Academy of Science found patient dropout rates to be as high as 30% in clinical trials. In this article, find out how missing outcome data caused by patient dropout and poor compliance not only jeopardizes the scientific validity of a study, but also comes at a significant financial cost to sponsors.

  • Recent technological innovations have expanded the potential for the collection of real-world evidence (RWE) in clinical trials. Read how t hrough patients’ personal devices, fixed in-home sensors, or third-party wearable devices (e.g., Fitbit) and biological sensors, researchers can now collect ecologically valid data representing a wide array of constructs.

  • Traditional clinical trials are multi-site human studies that integrate numerous in-person study visits and endpoints. However, as clinical studies become more complex, it is more important than ever to develop new trial models that can accommodate novel endpoints and provide greater flexibility to study participants.

  • How do we want to transform electronic clinical outcome assessments (eCOAs) – including electronic patient-reported outcomes (ePROs) – to drive better patient engagement in the short, mid and long term? There are many possible answers to that question. In this blog we focus on three opportunities to frame the future.

  • Amid growing availability, interest, and confusion around using sensors and other devices to improve clinical trials, this article offers a roundup of key considerations and compelling use cases.

  • In this study we examined geofencing data for two independent sub-studies using the Linkt geofencing feature – an observational community-based study of COVID-19 (N=360) and a vaccine clinical trial by a major pharmaceutical company (N=40). This preliminary report summarizes the real-world performance of geofencing for automatic detection of geofence crossings.

  • Clinical research studies involving repeated patient reported outcome measures (PROs) face several challenges. Patients may fail to complete individual PROs, whether at all or within a specified time (i.e., reduced compliance). Patients may cease participating in a study altogether, dropping out before all study procedures are completed (i.e., reduced retention). Read how an app was used in a study that enrolled 124 patients resulted in the majority of participants in the study being 100% compliant and retained through study end.

  • Missing outcome data caused by patient dropout and poor compliance not only jeopardize the scientific validity of a study, but also come at a significant financial cost to study sponsors. Technology and behavioral science offer potential solutions that together can address these challenges through patient-centric design of tools. This case study examines retention and compliance in a multicenter, open-label clinical trial (N=36) with the use of the Linkt mobile application.

  • This paper explains how a platform and patient app with gamification element increases participant retention and compliance, with respect to the collection of patient-reported outcomes data, when deployed in research studies.

  • Central nervous system (CNS) trials present unique challenges in terms of patient engagement and data collection. Discover how combining behavioral science with innovative technology can reshape the success of a CNS study.

  • Clinical studies take too long, and they cost too much. As a result, it takes too long to bring new drugs to market. What techniques can pharmaceutical companies develop and deploy to bring drugs to market faster, at lower cost, and with greater compliance among study subjects? We looked at other industries for inspiration and learned by adopting and adapting best practices from other sectors they could overcome these challenges.

  • In this paper we explain how to use principles of behavioral economics to keep clinical trial participants engaged, adherent, and proud of their contributions to curing diseases.

  • Industry perception is that the start-up costs of implementing an ePRO platform may dwarf the cost of printing and distributing paper diaries by as much as 10 times. However, this does not take into consideration the significant value and return on investment that adopting ePRO technology has had on overall clinical trial costs and timelines due to improvements in data quality and completeness, participant retention and compliance, and study and site efficiency.